1.	Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: WHC-MRI-GU-2006-097, NCT00397761
2.	Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GBG-GEPARQUATTRO, GBG-40, EU-205101, AVENTIS-GBG-GEPARQUATTRO, ROCHE-AVENTIS-GBG-GEPARQUATTRO, EUDRACT-2005-001546-17, NCT00288002
3.	A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer Phase: Phase III Type: Genetics, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GBG 44, EudraCT No.: 2006-005834-19, NCT00567554
4.	A Study to Compare Subcutaneous Versus Intravenous Administration of Herceptin (Trastuzumab) in Women With HER2Positive Early Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BO22227, 2008-007326-19, NCT00950300
5.	Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: CAN-NCIC-MA22, NCT00066443, MA22
6.	Docetaxel and Lapatinib With or Without Combination Chemotherapy or Docetaxel and Trastuzumab With Combination Chemotherapy in Treating Women With Locally Advanced, Inflammatory, or Resectable Breast Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 70 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: EORTC-10054, GSK-EORTC-10054, EUDRACT-2006-000864-94, NCT00450892
7.	Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 105-08-201, NCT00826085
8.	Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 65 and under Sponsor: NCI Protocol IDs: CHNMC-05042, IRB 05042, NCT00182793
9.	Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 0903-882, 0309006307, NCT00195091
10.	Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CHNMC-05015, IRB 05015, NCT00295893
11.	Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients Phase: Phase II Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: GEICAM/2006-03, NCT00432172
12.	Oxidized Glutathione (NOV-002), Doxorubicin, Cyclophosphamide, and Docetaxel in Treating Women With Newly Diagnosed Stage IIB, or Stage IIIC Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MUSC-101072, MUSC-HR-17111, 101072, NCT00499122
13.	Sunitinib and Combination Chemotherapy Before Surgery in Treating Patients With Stage II or Stage III Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UWCC-6488, 6488, UWCC-UW-6488, UWCC-07-6437-H/A, NCT00513695
14.	Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 19 and over Sponsor: Other Protocol IDs: F061229006, UAB 0648, NCT00530868
15.	Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: LJCC 07-03, NCT00542191
16.	Phase II Neoadjuvant in Inflammatory Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2007-0818, NCT00756470
17.	Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Inflammatory Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: FNCLCC-PACS-09/0802, Beverly 1, FNCLCC-PACS-09/0802-Beverly 1, EudraCT-2008-001807-53, EU-20889, NCT00820547
18.	Study of Neoadjuvant Chemotherapy of Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: CCAM 07-03, NCT00830544
19.	Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: Adult Sponsor: NCI Protocol IDs: SWOG-S0800, S0800, NCT00856492
20.	Treatment With Pazopanib for Neoadjuvant Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 110264, NSABP FB-6, NCT00849472
21.	Study of XL184 in Adults With Advanced Malignancies Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XL184-203, NCT00940225
22.	A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: PROMIX, EudraCT number: 2007-005858-23, NCT00957125
23.	A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Patients With HER2-Positive Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BO22280, 2009-012019-17, NCT00976989
24.	Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: NSABP FB-7, NCT01008150
25.	Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: 2008-0372, NCT01036087